Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

WithSecure’s new tech is an ‘undo’ button for ransomware

WithSecure’s Activity Monitor technology rolls back changes to data caused by malware.Helsinki, Finland – February 23, 2023: Ransomware attacks have plagued organizations for the past several years, inflicting considerable financial losses. To help organizations manage ransomware and other threats, WithSecure ™ (formerly known as F-Secure Business) has developed a new technology that can essentially undo the damage malware can cause. The technology, called Activity Monitor, was developed to make the capabilities of a sandbox more accessible. Sandboxes are

Veidekke: Shares purchased by employees in 2023 and Exercise of employee share options Key employees

With reference to the stock exchange notice dated February 20, 2023, primary insider notifications pursuant to the market abuse regulation article 19 are attached. For further information, please contact: Jørgen Wiese Porsmyr, CFO, +47 907 59 058, jorgen-wiese.porsmyr@veidekke.no This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

BioStock: Advancements for Elicera in 2022 open for intensive clinical year

In 2022, Elicera Therapeutics – the only Swedish R&D company developing CAR T-cell therapies in Sweden – advanced on several fronts. The company received a total of more than SEK 30 million in grants which finance, among other things, its clinical activities. In addition to the company taking important steps in business development, new positive research results with the company’s oncolytic virus were also presented. Furthermore, Elicera recently applied to start the first clinical trial with the company’s CAR T treatment ELC-301. If approved, it would pave the way for an intensive clinical

Zound delivered second consecutive year of record-breaking performance

Zound Industries has achieved new highs with a second year in a row of record revenues. Net sales rose 44 percent to SEK 3,102 million with Zound breaking the 3 billion SEK barrier and hitting double-digit profitability with an operating margin of 10.3 percent, equivalent to an operating profit of SEK 319 million. With strong growth across all product categories, channels, markets, and showing profitability in all four quarters, 2022 was Zound’s best year to date.Zound is the powerhouse behind the Marshall, adidas and Urbanears speakers and headphones brands. The company is on a mission to

Ellevio AB Year-end Report 2022

Key financials January–December 2022 · Net sales amounted to SEK 7,535 million (7,153) · Distributed electricity amounted to a total of 25.0 TWh (27.5) · Operating profit amounted to SEK 2,085 million (1,973) · Free cash flow totalled SEK 1,549 million (1,194) · Capital expenditure, including asset acquisitions, amounted to SEK 3,345 million (3,590) The Year-end Report comments on important aspects of Ellevio’s operations during the period, including the recent development of the regulatory framework. The report is available on Ellevio’s website: www.ellevio.se/en/

Fazer discontinues its dairy business at the Koria factory

The change negotiations concerning Fazer’s dairy operations at the Koria factory have been concluded. As a result, the dairy business will be discontinued by the end of August 2023. In addition, efficiency improvements related to the supply chain will be made, which are inevitable to maintain the company’s competitiveness.During the change negotiations, Fazer evaluated several different options to improve the efficiency of its dairy business and all factory operations in Koria. The company has decided to discontinue the dairy business by the end of August 2023. In addition, Fazer will

IAR Embedded Workbench supports the most cost-effective STM32 MCU series

IAR and STMicroelectronics help developers of cost-sensitive applications to move from 8-/-16-bit MCUs to the new entry-level 32-bit STM32 MCU seriesUppsala, Sweden—February 23, 2023 – STMicroelectronics’ new STM32C0 series promises to make 32-bit capabilities accessible to all developers at a low price. Now, IAR, the world leader in software and services for embedded development, an ST Authorized Partner, announces the support for this latest addition to the popular STM32 microcontrollers. The powerful IAR Embedded Workbench for Arm has powerful capacities for building an optimized and

Södra investigates new large-scale sawmill – initiates preliminary project

Södra has decided to investigate the conditions for a new large-scale sawmill in Kinda in Östergötland. A preliminary project will be undertaken and serve as a basis for a future investment decision.Södra’s assignment is to improve and renew the value of forest estates. A key part of the association’s Group strategy is a future-proof industrial structure that continuously creates a leading offering for customers and consumers. The association’s sawmills play a central role in this work and Södra has therefore now decided to launch a preliminary project to study the conditions for the

CO2 Capsol – Presentation at Pareto Securities’ Power & Renewable Energy Conference 28 February 2023

Oslo, Norway - 23 February 2023CO2 Capsol’s Chief Financial Officer Ingar Bergh will be presenting at thePareto Securities´ 25th annual Power & Renewable Energy Conference 28 February2023 at 15:10 CET.Link to the conference: https://paretosec.com/power-and-renewable-conferenceFor further information, please contact:Ingar BerghChief Financial OfficerCO2 Capsol AS+47 926 20 330ingar.bergh@co2capsol.comAbout CO2 CapsolCO2 Capsol is a carbon capture technology provider with a goal to accelerate thetransition to a carbon negative future. The company’s energy efficient,

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 51 - 23 FEBRUARY 2023 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 40/23 and 42/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor Communications Partner, tel.: 3315 0451

Renewal of Wärtsilä Maintenance Agreement emphasises continuation of a successful collaboration

Wärtsilä Corporation, Trade press release, 23 February 2023 at 10.30 AM EETThe technology group Wärtsilä has signed a five-year renewal of its existing Maintenance Agreement  with Norway’s Höegh LNG Fleet Management (HLNG). The renewed agreement includes delivery of spare parts and field maintenance services, as well as Wärtsilä’s latest digital solutions and extends the value-adding cooperation between the two companies. The order was included in Wärtsilä’s order book in December 2022. The agreement covers maintenance on the Wärtsilä 50DF dual-fuel engines

House of Rare disrupts investing and trading of scarce collectibles, launching the first asset-backed NFT marketplace on Concordium blockchain.

February 23, 2023 - Zug, Switzerland - The Concordium blockchain will be used to launch House of Rare’s asset-backed NFT marketplace for fine spirits, leveraging Concordium’s novel ID framework to ensure that end user have the necessary attributes for the purchase for vendors legal compliance, such as age and jurisdictions.House of Rare pioneered real item-backed NFTs with their first collection - RAREtequila. The collection consists of 777 NFTs, each redeemable for a bottle of highend limited edition tequila. The future plan is to branch out into the world of fine wine, champagne and

BioStock: CombiGene’s pain project receives new scientific support

At the beginning of the year, CombiGene entered into a collaboration agreement with the Danish company Zyneyro for the development of a treatment for severe temporary and chronic pain conditions. A new doctoral thesis at the University of Copenhagen now shows robust pain relief with the current drug candidates in experimental models.Read the article at biostock.se: https://www.biostock.se/en/2023/02/combigenes-pain-project-receives-new-scientific-support/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Gradientech: Year-end Report 2022

The year-end report 2022 for Gradientech AB (publ) is now available on the company's website www.gradientech.se.Fourth quarter October-December 2022 · Net sales amounted to KSEK 831 (KSEK 0). · Profit after tax amounted to KSEK -16,409 (KSEK -17,859). · Earnings per share before and after dilution were SEK -1.03 (SEK -1.46). · Inline with the commercialisation of the QuickMIC® system, Gradientech has started accounting for Inventory, which had a positive one-off effect on the result with KSEK 3,529. · Cash flow from current operations amounted to KSEK -19,550 (KSEK -17,286).

INTERIM REPORT OCTOBER 1st 2022 – DECEMBER 31st 2022

SELECTIMMUNE PHARMA IN BRIEF SelectImmune Pharma is an innovative biotech company that develops novel immunotherapies against infection. • Excessive innate immune responses to infection cause symptoms and pathology in acute pyelone phritis and acute cystitis. Immunomodulation is therefore a realistic option for treating these condi tions as alternatives or complements to antibiotics. • Several of the company’s drug candidates have shown protective effects against bacterial infection in animal models, including acute cystitis, severe kidney infection and urosepsis. • One drug

Sleep Cycle Launches ‘Sleep Cycle Kids’ - an app that enables parents to track, analyze and improve their children’s sleep

February 23, 2023, Gothenburg - Sleep Cycle, the market-leading sleep tracker, today announced the launch of ‘Sleep Cycle Kids’,  a science-based app providing parents with tools to optimize the children’s sleep - and how to help their kids sleep better to optimize well-being for the whole family.Sleep Cycle Kids is centered around an intelligent sleep schedule that adapts to each individual child and  gives parents the tools to determine the optimal bedtime, reduce the time it takes to fall asleep, and identify and change other behaviors that can be problematic for children’s sleep.  An

Wicket Gaming invites to investor meeting in Stockholm, February 28, 2023

In connection with the publication of the year-end report 2022 and the ongoing rights issue which extends until and including March 7, the Company invites shareholders and the public to an investor meeting on February 28, 2023.   The investor meeting is held on Elite Hotel Stockholm Plaza on Tuesday February 28 at 17:00 on Birger Jarlsgatan 29, Stockholm. Eric De Basso, CEO of Wicket Gaming, will present the company and hold a questions and answers sessions. Coffee and tea will be offered during the investor meeting.   To join online, use the following link: Join on YouTube (

Kappahl is donating more than three million Swedish kronor to sustainable development organisations

Kappahl’s customers are continuing to use fewer plastic bags – since the industry’s One Bag Habit initiative was introduced in 2017 there has been an impressive 78 per cent reduction. And the profits from bags purchased by customers in stores are donated to organisations promoting sustainable development. In 2022, a total of over three million Swedish kronor was donated. Greater use of fewer bags – that’s the aim of the One Bag Habit, an industry initiative that calls on its member organisations, Kappahl included, to charge for carrier bags in their stores. The objective is

Year End Report 2022 - Ayima Group AB

Highlights  Year: Jan - Dec 2022 · Revenue amounted to 149.9 MSEK (160.5), a decrease of 7% from 2021 · Gross Profit amounted to 81.4 MSEK (85.8), a decrease of 5% from 2021  · Operating costs amounted to 78.8 MSEK (68.4), an increase of 15% from last year · A positive EBITDA result of 2.6 MSEK (17.4) · EBITDA margin decreased to 2% (11%) · Net Profit after tax for the period was -5.7 MSEK (8.9) Q4 Oct -Dec 2022 · Revenue amounted to 39.1 MSEK (40.3), a decrease of 3% from the corresponding period in 2021 · Gross Profit amounted to 16.9 MSEK (23.0), a

Join us on March 16 for the next virtual BioStock Investor Meeting

You are invited to watch as life science companies from a number of therapeutic areas present their business cases to investors and potential partners.The event will be broadcasted on the BioStock website and on our YouTube channel. You can also access the event through our social media platforms.   See you at 10 am on March 16!  Stay updated on the latest news about our events by signing up for our newsletter at https://www.biostock.se/en/  or visiting our event site https://www.biostock.se/en/eventcalendar/.

Medivir to present at the Erik Penser Bank Healthcare Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Erik Penser Bank Healthcare Day today, February 23, 2023. CEO Jens Lindberg will present the company and its plan for the ongoing clinical study with fostroxacitabine bralpamide (fostrox).   The presentation will be available after the meeting on Medivirs website; www.medivir.com.   For additional information, please contactMagnus Christensen, CFO, Medivir AB

Ellos Group AB (publ) interim report january – december 2022

Press release, Borås 23 February 2023 The interim report for Ellos Group AB (publ) is published today.THE FOURTH QUARTER 2022 •    Net sales decreased by 1.9 % to SEK 1 038.9 (1 059.3) million. Organically, net sales was unchanged.•    The gross margin decreased to 49.1 (50.6) %.•    Adjusted EBITA amounted to SEK 26.5 (38.9) million. The adjusted EBITA margin stood at 2.5 (3.7) %.•    The operating profit/loss amounted to SEK -11.6 (10.4) million. The operating margin was -1.1 (1.0) %.•    Cash flow from operating activities amounted to SEK 68.6 (43.5) million.•    Cash and

Freetrailer Group A/S quarterly report Q2 22/23

MARFreetrailer has delivered another quarter of growth, with the number of rentals increasing by 15% compared to Q2 21/22, and revenue growing by 26%.Freetrailer Group A/S presents the Q2 quarterly report for the Group for the financial period 01 October 2022 - 31 December 2022.   Q2 GROUP KEY FIGURES IN 1.000 DKK (01 October 2022 - 31 December 2022) (the corresponding period last year is indicated in brackets) - Revenue 17,751.7 (14,093.3) - EBITDA 1,537.8 (2,313.1) - Profit before tax 1,148.5 (1,861.3) - Profit after tax 830.7 (1,451.8) - Equity 31,361.3 (22,140.

Hamlet Pharma AB: Hamlet Pharma Q2 Interim Report October 2022 – December 2022

Opening remarks During the second quarter of the fiscal year, Hamlet Pharma has made significant progress in its clinical trial program for Alpha1H, a drug candidate in the HAMLET family, as a standalone treatment for bladder cancer patients. The company has also continued its collaboration with Neurochase for the treatment of brain tumors with Alpha1H and its collaboration with Linnane Pharma, to define the potential of BAMLET as a drug candidate.Bladder cancer Alpha1H targets and effectively kills tumor cells in patients with bladder cancer. The placebo-controlled study has

There are no items matching the current filter
There are no more items matching the current filter
Back to top